Cholera Vaccines Market Growth, Industry Trends, Analysis and Forecast 2024-2032
IMARC Group, a leading market research company, has recently releases report titled “Cholera Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global cholera vaccines market growth, share, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Cholera Vaccines
Cholera vaccines are preventive measures designed to protect individuals from cholera, a bacterial infection caused by the Vibrio cholerae bacterium. They work by stimulating the immune system to produce protective antibodies against the cholera toxin. They are widely available as oral cholera vaccines (OCVs) and injectable cholera vaccines (ICVs). They play a vital role in reducing the severity and spread of cholera and preventing severe dehydration, hospitalization, and death while improving overall health outcomes. They are crucial for travelers visiting regions with known cholera outbreaks or endemic areas. As they assist in lowering the risk of contracting the disease, even in high-risk areas with contaminated water sources and poor sanitation, the demand for cholera vaccines is increasing across the globe.
How Big Is the Cholera VaccinesMarket?
The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032.
Request Sample Copy of This Report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample
What are the growth prospects and trends in the cholera vaccinesindustry?
At present, rising concerns about infectious diseases among the masses represents one of the major factors strengthening the growth of the market. Besides this, the growing demand for cholera vaccines among tourists and business travelers is offering a positive market outlook. In addition, the increasing development of more effective and affordable cholera vaccines is impelling the market growth. Apart from this, the rising number of specialized travel medicine clinics around the world is offering lucrative growth opportunities to industry investors.
Moreover, the escalating demand for cholera vaccines to safeguard the health and well-being of people is positively influencing the market. In line with this, improving disease surveillance systems allows for the identification of high-risk areas of cholera diseases, which is propelling the market growth. Furthermore, advancements in vaccine technology, such as the development of new formulations and delivery methods, are contributing to the growth of the market.
Additionally, governing agencies of several countries are organizing cholera-related vaccination campaigns to lower the severity and spread of cholera disease among individuals. They are also generating awareness about the harmful effects of cholera through educational campaigns, which is bolstering the market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Vaccine Type:
- Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- Killed Oral O1 and O139
Breakup by Product:
- Dukoral
- Shanchol
- Vaxchora
- Euvichol and Euvichol-Plus
- Others
Breakup by End User:
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Astellas Pharma Inc.
- Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
- Emergent BioSolutions Inc.
- Eubiologics Co. Ltd.
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- PharmaChoice Canada Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Valneva SE
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian